

(FILE 'HOME' ENTERED AT 12:26:33 ON 29 JUN 2003)

FILE 'REGISTRY' ENTERED AT 12:26:42 ON 29 JUN 2003

L1 STRUCTURE UPLOADED  
L2 4 S L1 SSS SAM  
L3 70 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE, USPATFULL, EUROPATFULL' ENTERED AT 12:28:14 ON 29 JUN 2003

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:28:41 ON 29 JUN 2003

L4 86 S L3  
L5 8 S L4 AND (HEPATITIS C OR HCV)


L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:695725 CAPLUS  
 DOCUMENT NUMBER: 137:210908  
 TITLE: Nucleotides, preparation thereof, and use as inhibitors of RNA viral polymerases  
 INVENTOR(S): Montgomery, John A.; Babu, Yarlagadda S.; Rowland, R. Scott; Chand, Pooran  
 PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069903	A2	20020912	WO 2002-US6551	20020306
WO 2002069903	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
 US 2001-273342P P 20010306  
 US 2001-285698P P 20010424  
 US 2001-331323P P 20011114

OTHER SOURCE(S): MARPAT 137:210908  
 GI



AB Antiviral nucleotides I were prepd. as inhibitors of RNA viral polymerases (no data), wherein X is selected from the group consisting of: O, S, N-R1, and CHR1; Y and Y' is individually selected from H, OR1, NR1R2, and N3; Z and Z' is individually selected from H, OR1, and NR1R2; R = H, monophosphate PO3R32, diphosphate P2O6R33, triphosphate P3O9R34; R1 and R2 is selected from H, alkyl, acyl, aryl which may be substituted or unsubstituted; R3 is selected from H, alkyl, alkenyl, alkynyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl; B is selected from 5 or 6-substituted uracil or cytosine, pseudouracil, N-substituted pseudouracil, 2-thiouracil, 2-thiocytosine, 5- or 6-substituted 2-thiouracil and 2-thiocytosine, 6-azauracil, 5-azacytosine, 8-azapurines, and 7-aza-8-deazapurines. Substitutions may be halo-substituted alkyl, halo-substituted alkenyl, halo-substituted alkynyl, halo-substituted aryl, alkylthio, or NR1R2. When Z and Z' are H and Y or Y' is OH then B is not 5-Me uracil or cytosine; and pharmaceutically acceptable salts thereof, mono, di or triphosphate and prodrugs thereof. Thus, 1-(3'-deoxy-.beta.-D-ribofuranosyl)-2-thiocytosine was prepd. as inhibitors of RNA viral polymerases (no data).


IT 70580-87-9P 70580-88-0P

RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified);  
BIOL (Biological study); PREP (Preparation)  
(Nucleotides, prepn. thereof, and use as inhibitors of RNA viral  
polymerases)

RN 70580-87-9 CAPLUS

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70580-88-0 CAPLUS

CN Uridine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:555629 CAPLUS

DOCUMENT NUMBER: 137:125359

TITLE: Preparation of nucleoside derivatives as inhibitors of  
RNA-dependent RNA viral polymerase

INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn  
L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,  
Malcolm; Olsen, David B.; Rutkowski, Carrie A.;  
Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;  
Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;  
Guinosso, Charles J.; Prhavic, Marija; Prakash, Thazha  
P.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002147160 A1 20021010 US 2002-52318 20020118  
PRIORITY APPLN. INFO.: US 2001-263313P P 20010122  
US 2001-282069P P 20010406  
US 2001-299320P P 20010619  
US 2001-344528P P 20011025

OTHER SOURCE(S): MARPAT 137:125359  
GI



AB The present invention provides the prepn. of nucleoside compds. I, wherein B is nucleobase, Y is H, alkylcarbonyl, phosphate; R1 is H, alkenyl, alkynyl, alkyl; R2 and R3 are independently H, OH, halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylcarbonyloxy, aryloxycrbonyl, azido, amino, alkylamino; R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered heterocycle; R4 is H, OH, SH, NH2, alkylamino, cycloalkylamino, halogen, alkyl, alkoxy, CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of **hepatitis C** virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of **hepatitis C** infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular **HCV** infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the **HCV** NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of **Hepatitis C** Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic **HCV** Replicon.

IT 123402-24-4P 123402-25-5P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 123402-24-4 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-25-5 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:504634 CAPLUS

DOCUMENT NUMBER: 137:57536

TITLE: Remedies for **hepatitis C**

INVENTOR(S): Morioka, Masahiko; Ubasawa, Masaru; Arai, Masaaki

PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051425	A1	20020704	WO 2001-JP11365	20011225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			JP 2000-394620	A 20001226
			JP 2001-23542	A 20010131
			JP 2001-105585	A 20010404

OTHER SOURCE(S): MARPAT 137:57536

AB Excellent remedies for **hepatitis C** which contain as the active ingredients a 3'-deoxy-3'-fluorouridine deriv. and a

1-(3'-deoxy-3'-fluoro-.beta.-L-ribofuranosyl)uracil deriv. and show little side effects.

IT 57944-13-5DP, 3'-Deoxy-3'-fluorouridine, derivs.

112668-56-1P 123402-24-4P 125217-37-0P

439579-20-1P 439579-21-2P 439579-22-3P

439579-24-5P 439579-25-6P 439579-26-7P

439579-28-9P 439579-32-5P 439579-34-7P

439579-36-9P 439579-37-0P 439579-38-1P

439579-40-5P 439579-41-6P 439579-42-7P

439579-43-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(deoxy-3'-fluorouridine deriv. and a 1-(3'-deoxy-3'-fluoro--L-ribofuranosyl)uracil deriv. as remedies for **hepatitis**

C)

RN 57944-13-5 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 112668-56-1 CAPLUS

CN Uridine, 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-24-4 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-20-1 CAPLUS

CN Uridine, 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-21-2 CAPLUS


CN Uridine, 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-22-3 CAPLUS  
CN Uridine, 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-24-5 CAPLUS  
CN Uridine, 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-25-6 CAPLUS  
CN Uridine, 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-26-7 CAPLUS  
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-L-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 439579-28-9 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-L-ribofuranosyl)-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-32-5 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-34-7 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-36-9 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 5-cyano-3'-deoxy-3'-fluoro- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-37-0 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-38-1 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 5-bromo-3'-deoxy-3'-fluoro- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-40-5 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-2-thio- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-41-6 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-4-thio- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-42-7 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-  
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-  
 ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-43-8 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-  
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-  
 ribofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:314958 CAPLUS  
 DOCUMENT NUMBER: 136:340939  
 TITLE: Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation  
 INVENTOR(S): Stuyver, Lieven; Watanabe, Kyoichi A.  
 PATENT ASSIGNEE(S): Pharmasset Limited, USA  
 SOURCE: PCT Int. Appl., 230 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032920	A2	20020425	WO 2001-US46113	20011018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002028749	A5	20020429	AU 2002-28749	20011018
US 2003087873	A1	20030508	US 2001-45292	20011018
PRIORITY APPLN. INFO.:			US 2000-241488P	P 20001018
			US 2001-282156P	P 20010406
			WO 2001-US46113	W 20011018

GI



AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH<sub>2</sub>, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R<sub>1</sub> are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH<sub>2</sub>, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO<sub>2</sub>, NO, CH<sub>2</sub>OH, CH<sub>2</sub>OH, ester, CONH<sub>2</sub>, amide, CN; R<sub>2</sub> and R<sub>3</sub> are independently H, halogen, OH, SH, OMe, SMe, NH<sub>2</sub>, NHMe, CH:CH<sub>2</sub>, CN, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>OH, CO<sub>2</sub>H; were prepd. for treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and esp. humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amt. of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepd. and tested in vitro as antiviral and antitumor agent.


IT 60786-48-3P 415704-55-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 60786-48-3 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 415704-55-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-L-arabinofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:171918 CAPLUS

DOCUMENT NUMBER: 136:217007

TITLE: Preparation of antiviral nucleoside derivatives as inhibitors of subgenomic hepatitis C virus RNA replication

INVENTOR(S): Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018404	A2	20020307	WO 2001-EP9633	20010821
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003008841	A1	20030109	US 2001-923620	20010807
AU 2001095497	A5	20020313	AU 2001-95497	20010821
EP 1315736	A2	20030604	EP 2001-976128	20010821
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: GB 2000-21285 A 20000830  
GB 2000-26611 A 20001031  
WO 2001-EP9633 W 20010821

OTHER SOURCE(S): MARPAT 136:217007

GI



AB Nucleosides I, wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepd. as inhibitors of subgenomic **hepatitis C virus (HCV)** RNA replication.

Thus, nucleoside II was prepd. and tested for the inhibition of **HCV** RNA replication (EC50 = 0.6 .mu.M).

IT **26563-01-9P 125217-37-0P 129885-95-6P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antiviral nucleoside derivs. as inhibitors of subgenomic **hepatitis C virus** RNA replication)

RN 26563-01-9 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 CAPLUS


CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 CAPLUS  
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:617773 CAPLUS  
DOCUMENT NUMBER: 135:175346  
TITLE: Method for the treatment or prevention of flavivirus  
infections using nucleoside analogues  
INVENTOR(S): Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing;  
Lavallee, Jean-Francois; Siddiqui, Arshad; Storer,  
Richard  
PATENT ASSIGNEE(S): Biochem Pharma Inc., Can.  
SOURCE: PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060315	A2	20010823	WO 2001-CA197	20010219
WO 2001060315	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001035278	A5	20010827	AU 2001-35278	20010219
EP 1296690	A2	20030402	EP 2001-907276	20010219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002019363	A1	20020214	US 2001-785235	20010220
NO 2002003884	A	20021017	NO 2002-3884	20020816
PRIORITY APPLN. INFO.:			US 2000-183349P	P 20000218
			WO 2001-CA197	W 20010219
OTHER SOURCE(S): MARPAT 135:175346				
AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogs in a host comprising administering a therapeutically effective amt. of the nucleoside analog or a pharmaceutically acceptable salt thereof.				
IT 70580-87-9 85708-20-9 123402-20-0 123402-25-5				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES				




(Uses)

(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to **hepatitis C** virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 CAPLUS

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 85708-20-9 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-20-0 CAPLUS

CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-25-5 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 7 OF 8 USPATFULL

ACCESSION NUMBER: 2003:11137 USPATFULL

TITLE: Anti-HCV nucleoside derivatives

INVENTOR(S): Devos, Rene, Welwyn Garden City, UNITED KINGDOM  
 Dymock, Brian William, St. Albans, UNITED KINGDOM  
 Hobbs, Christopher John, Hertford, UNITED KINGDOM  
 Jiang, Wen-Rong, Welwyn Garden City, UNITED KINGDOM  
 Martin, Joseph Armstrong, Harpenden, UNITED KINGDOM  
 Merrett, John Herbert, Baldock, UNITED KINGDOM  
 Najera, Isabel, St. Albans, UNITED KINGDOM  
 Shimma, Nobuo, Chigasaki-shi, JAPAN  
 Tsukuda, Takuo, Odawara-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008841	A1	20030109
APPLICATION INFO.:	US 2001-923620	A1	20010807 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-21285	20000830
	GB 2000-26611	20001031
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4872	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against **hepatitis C** virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein..


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **26563-01-9P 125217-37-0P 129885-95-6P**  
 (prepn. of antiviral nucleoside derivs. as inhibitors of subgenomic hepatitis C virus RNA replication)

RN 26563-01-9 USPATFULL


CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 125217-37-0 USPATFULL  
 CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 USPATFULL  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER: 2002:32541 USPATFULL

TITLE: Method for the treatment or prevention of flavivirus infections using nucleoside analogues

INVENTOR(S): Ismaili, Hicham Moulay Alaoui, Montreal, CANADA  
 Cheng, Yun-Xing, Dollard-des-Ormeaux, CANADA  
 Lavallee, Jean-Francois, Bellefeuille, CANADA  
 Siddiqui, Arshad, Dollard-des-Ormeaux, CANADA  
 Storer, Richard, Baie d'Urfe, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019363	A1	20020214
APPLICATION INFO.:	US 2001-785235	A1	20010220 (9)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2000-183349P 20000218 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, PC, 2200 CLARENDON  
BLVD, SUITE 1400, ARLINGTON, VA, 22201  
NUMBER OF CLAIMS: 18  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 70580-87-9 85708-20-9 123402-20-0  
123402-25-5

(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 USPATFULL

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 85708-20-9 USPATFULL

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-20-0 USPATFULL

CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-25-5 USPATFULL

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



=>

(FILE 'HOME' ENTERED AT 12:47:36 ON 29 JUN 2003)

FILE 'REGISTRY' ENTERED AT 12:48:27 ON 29 JUN 2003

L1 STRUCTURE UPLOADED  
L2 70 S L1 SSS FULL



FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:49:35 ON 29 JUN 2003

L3 86 S L2

FILE 'CAPLUS, MEDLINE, USPATFULL, AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, ...' ENTERED AT 12:50:16 ON 29 JUN 2003

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:51:09 ON 29 JUN 2003

L4 86 S L3  
L5 8 S L3 AND (HCV OR HEPATITIS C)  
L6 19 S L4 AND ANTIVIRAL



chain nodes :

6 7 8 9 10 13 14 16 17 18 19 20 21 22 23 27

ring nodes :

1 2 3 4 5 28 29 30 31 32 33

chain bonds :

1-7 2-13 2-14 3-6 5-28 6-16 8-9 9-10 16-27 17-18 17-19 17-20 21-22 21-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 28-33 28-29 29-30 30-31 31-32 32-33

exact/norm bonds :

1-2 1-5 1-7 2-3 2-13 2-14 3-4 4-5 5-28 8-9 9-10 16-27 17-18 17-19 17-20  
21-22 21-23 28-33 28-29 29-30 30-31 31-32 32-33

exact bonds :

3-6 6-16

G1:F, [\*1]

G2:H, [\*2], [\*3]

G3:OH, MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO, PhO

G4:G1, H

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:CLASS  
14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom

Generic attributes :

23:  
Number of Carbon Atoms : less than 7


ACCESSION NUMBER: 2002:695725 CAPLUS  
 DOCUMENT NUMBER: 137:210908  
 TITLE: Nucleotides, preparation thereof, and use as inhibitors of RNA viral polymerases  
 INVENTOR(S): Montgomery, John A.; Babu, Yarlagadda S.; Rowland, R. Scott; Chand, Pooran  
 PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069903	A2	20020912	WO 2002-US6551	20020306
WO 2002069903	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
 US 2001-273342P P 20010306  
 US 2001-285698P P 20010424  
 US 2001-331323P P 20011114

OTHER SOURCE(S): MARPAT 137:210908  
 GI



AB **Antiviral** nucleotides I were prepd. as inhibitors of RNA viral polymerases (no data), wherein X is selected from the group consisting of: O, S, N-R1, and CHR1; Y and Y' is individually selected from H, OR1, NR1R2, and N3; Z and Z' is individually selected from H, OR1, and NR1R2; R = H, monophosphate PO3R32, diphosphate P2O6R33, triphosphate P3O9R34; R1 and R2 is selected from H, alkyl, acyl, aryl which may be substituted or unsubstituted; R3 is selected from H, alkyl, alkenyl, alkynyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl; B is selected from 5 or 6-substituted uracil or cytosine, pseudouracil, N-substituted pseudouracil, 2-thiouracil, 2-thiocytosine, 5- or 6-substituted 2-thiouracil and 2-thiocytosine, 6-azauracil, 5-azacytosine, 8-azapurines, and 7-aza-8-deazapurines. Substitutions may be halo-substituted alkyl, halo-substituted alkenyl, halo-substituted alkynyl, halo-substituted aryl, alkylthio, or NR1R2. When Z and Z' are H and Y or Y' is OH then B is not 5-Me uracil or cytosine; and pharmaceutically acceptable salts thereof, mono, di or triphosphate and prodrugs thereof. Thus, 1-(3'-deoxy-.beta.-D-ribofuranosyl)-2-thiocytosine was prepd. as inhibitors of RNA viral polymerases (no data).

IT 70580-87-9P 70580-88-0P




RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified);  
BIOL (Biological study); PREP (Preparation)  
(Nucleotides, prepn. thereof, and use as inhibitors of RNA viral  
polymerases)

RN 70580-87-9 CAPLUS

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70580-88-0 CAPLUS

CN Uridine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:555629 CAPLUS

DOCUMENT NUMBER: 137:125359

TITLE: Preparation of nucleoside derivatives as inhibitors of  
RNA-dependent RNA viral polymerase

INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn  
L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,  
Malcolm; Olsen, David B.; Rutkowski, Carrie A.;  
Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;  
Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;  
Guinosso, Charles J.; Prhavic, Marija; Prakash, Thazha  
P.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002147160 A1 20021010 US 2002-52318 20020118  
 PRIORITY APPLN. INFO.: US 2001-263313P P 20010122  
 US 2001-282069P P 20010406  
 US 2001-299320P P 20010619  
 US 2001-344528P P 20011025

OTHER SOURCE(S): MARPAT 137:125359  
 GI



AB The present invention provides the prepn. of nucleoside compds. I, wherein B is nucleobase, Y is H, alkylcarbonyl, phosphate; R1 is H, alkenyl, alkynyl, alkyl; R2 and R3 are independently H, OH, halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylcarbonyloxy, aryloxycrbonyl, azido, amino, alkylamino; R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered heterocycle; R4 is H, OH, SH, NH2, alkylamino, cycloalkylamino, halogen, alkyl, alkoxy, CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of Hepatitis C Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic HCV Replicon.


IT 123402-24-4P 123402-25-5P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 123402-24-4 CAPLUS


CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 CAPLUS  
 CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:504634 CAPLUS  
 DOCUMENT NUMBER: 137:57536  
 TITLE: Remedies for hepatitis C  
 INVENTOR(S): Morioka, Masahiko; Ubasawa, Masaru; Arai, Masaaki  
 PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan  
 SOURCE: PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051425	A1	20020704	WO 2001-JP11365	20011225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2000-394620	A 20001226
			JP 2001-23542	A 20010131
			JP 2001-105585	A 20010404

OTHER SOURCE(S): MARPAT 137:57536  
 AB Excellent remedies for hepatitis C which contain as the active ingredients a 3'-deoxy-3'-fluorouridine deriv. and a 1-(3'-deoxy-3'-fluoro-.beta.-L-ribofuranosyl)uracil deriv. and show little side effects.  
 IT 57944-13-5DP, 3'-Deoxy-3'-fluorouridine, derivs.  
 112668-56-1P 123402-24-4P 125217-37-0P

439579-20-1P 439579-21-2P 439579-22-3P  
 439579-24-5P 439579-25-6P 439579-26-7P  
 439579-28-9P 439579-32-5P 439579-34-7P  
 439579-36-9P 439579-37-0P 439579-38-1P  
 439579-40-5P 439579-41-6P 439579-42-7P  
 439579-43-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(deoxy-3'-fluorouridine deriv. and a 1-(3'-deoxy-3'-fluoro--L-ribofuranosyl)uracil deriv. as remedies for hepatitis C)

RN 57944-13-5 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 112668-56-1 CAPLUS

CN Uridine, 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-24-4 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-20-1 CAPLUS

CN Uridine, 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-21-2 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-22-3 CAPLUS


CN Uridine, 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-24-5 CAPLUS  
 CN Uridine, 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-25-6 CAPLUS  
 CN Uridine, 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-26-7 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-L-ribofuranosyl)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-28-9 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-L-ribofuranosyl)-5-

fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-32-5 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3',5-difluoro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439579-34-7 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-methyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-36-9 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 5-cyano-3'-deoxy-3'-fluoro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439579-37-0 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439579-38-1 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439579-40-5 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439579-41-6 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-4-thio- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439579-42-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439579-43-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-ribofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:314958 CAPLUS

DOCUMENT NUMBER: 136:340939

TITLE: Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation

INVENTOR(S): Stuyver, Lieven; Watanabe, Kyoichi A.

PATENT ASSIGNEE(S): Pharmasset Limited, USA

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032920	A2	20020425	WO 2001-US46113	20011018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002028749	A5	20020429	AU 2002-28749	20011018
US 2003087873	A1	20030508	US 2001-45292	20011018
PRIORITY APPLN. INFO.:			US 2000-241488P	P 20001018
			US 2001-282156P	P 20010406
			WO 2001-US46113	W 20011018

GI



AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH<sub>2</sub>, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R<sub>1</sub> are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH<sub>2</sub>, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO<sub>2</sub>, NO, CH<sub>2</sub>OH, CH<sub>2</sub>OH, ester, CONH<sub>2</sub>, amide, CN; R<sub>2</sub> and R<sub>3</sub> are independently H, halogen, OH, SH, OMe, SMe, NH<sub>2</sub>, NHMe, CH:CH<sub>2</sub>, CN, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>OH, CO<sub>2</sub>H; were prepd. for treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and esp. humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amt. of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepd. and tested in vitro as **antiviral** and antitumor agent.


IT 60786-48-3P 415704-55-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 60786-48-3 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 415704-55-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-L-arabinofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:171918 CAPLUS

DOCUMENT NUMBER: 136:217007

TITLE: Preparation of **antiviral** nucleoside derivatives as inhibitors of subgenomic hepatitis C virus RNA replication

INVENTOR(S): Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018404	A2	20020307	WO 2001-EP9633	20010821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003008841	A1	20030109	US 2001-923620	20010807
AU 2001095497	A5	20020313	AU 2001-95497	20010821
EP 1315736	A2	20030604	EP 2001-976128	20010821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			GB 2000-21285	A 20000830
			GB 2000-26611	A 20001031
			WO 2001-EP9633	W 20010821

OTHER SOURCE(S): MARPAT 136:217007

GI



AB Nucleosides I, wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepd. as inhibitors of subgenomic hepatitis C virus (HCV) RNA replication. Thus, nucleoside II was prepd. and tested for the inhibition of HCV RNA replication (EC50 = 0.6 .mu.M).

IT 26563-01-9P 125217-37-0P 129885-95-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of **antiviral** nucleoside derivs. as inhibitors of subgenomic hepatitis C virus RNA replication)

RN 26563-01-9 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 CAPLUS


CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 CAPLUS  
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:617773 CAPLUS  
DOCUMENT NUMBER: 135:175346  
TITLE: Method for the treatment or prevention of flavivirus  
infections using nucleoside analogues  
INVENTOR(S): Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing;  
Lavallee, Jean-Francois; Siddiqui, Arshad; Storer,  
Richard  
PATENT ASSIGNEE(S): Biochem Pharma Inc., Can.  
SOURCE: PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060315	A2	20010823	WO 2001-CA197	20010219
WO 2001060315	A3	20030116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001035278	A5	20010827	AU 2001-35278	20010219
EP 1296690	A2	20030402	EP 2001-907276	20010219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2002019363	A1	20020214	US 2001-785235	20010220
NO 2002003884	A	20021017	NO 2002-3884	20020816
PRIORITY APPLN. INFO.:			US 2000-183349P P	20000218
			WO 2001-CA197 W	20010219
OTHER SOURCE(S):	MARPAT 135:175346			
AB	The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogs in a host comprising administering a therapeutically effective amt. of the nucleoside analog or a pharmaceutically acceptable salt thereof.			
IT	70580-87-9 85708-20-9 123402-20-0 123402-25-5			
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES			


(Uses)

(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 CAPLUS

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 85708-20-9 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-20-0 CAPLUS

CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-25-5 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:594332 CAPLUS

DOCUMENT NUMBER: 131:317318

TITLE: QSAR studies of **antiviral** agents using molecular similarity analysis and structure-activity maps

AUTHOR(S): Parakulam, R. R.; Lesniewski, M. L.; Taylor-McCabe, K. J.; Tsai, C.

CORPORATE SOURCE: Department of Chemistry, Kent State University, Kent, OH, 44242-0001, USA

SOURCE: SAR and QSAR in Environmental Research (1999), 10(2-3), 175-206

CODEN: SQERED; ISSN: 1062-936X

PUBLISHER: Gordon & Breach Science Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Quant. structure-activity relationships (QSAR) were developed for nucleoside analogs with anti-HIV activity. These compds. were investigated to det. the correlation of structure and toxicity/activity using mol. similarity anal. and structure-activity maps. A multiple-formula approach was used to perform quant. mol. similarity anal. (QMSA) and QSAR study. Mol. descriptors such as no. of atoms and bonds of a mol. (NAB), max. common substructure (MaCS), and mol. similarity index (MSI) were used in the authors structure-activity relation study. The MaCS of two mols. is defined as the substructure with the greatest NAB value common to both mols. The MSI of two mols. X and Y is defined as  $MSI(X,Y) = [MaCS(X,Y)/NAB(X)] \cdot [MaCS(X,Y)/NAB(Y)]$ . MaCS and MSI quantify the similarity between two mol. structures. Structure-activity maps (structure-toxicity map and structure-**antiviral** map) and QMSA were used to det. the site and type of modification for reduced toxicity and improved activity of new compds.

IT 125217-37-0, Uridine, 3'-deoxy-3'-fluoro-5-methyl-

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(QSAR studies of **antiviral** pyrimidine nucleoside analogs with anti-HIV activity in relation to toxicity using mol. similarity anal. and structure-activity maps)

RN 125217-37-0 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:304337 CAPLUS

DOCUMENT NUMBER: 125:58994

TITLE: Preparation of 1-(3'-fluoro-2',3'-dideoxy-.beta.-D-ribofuranosyl)-5-substituted pyrimidine nucleosides as **antiviral** agents against HIV

INVENTOR(S): Johansson, Karl N. G.; Lindborg, Bjoeg; Norinder, Ulf; Stening, Goran B.

PATENT ASSIGNEE(S): Medivir Ab, Swed.

SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 802,706, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5506215	A	19960409	US 1994-354769	19941212
PRIORITY APPLN. INFO.:			SE 1987-4298	19871103
			US 1988-266402	19881102
			US 1990-518495	19900503
			US 1991-802706	19911206

OTHER SOURCE(S): MARPAT 125:58994

GI



I

AB The title 2',3'-deoxy-3'-fluoro-pyrimidine nucleosides (I; R1 = OH or NH2; R2 = CF3, n-Pr, cyclopropyl, CH2OMe, CH2SMe, CH:CH2, CH:CHMe, C.tplbond.CH, C.tplbond.CMe, CH2C.tplbond.CH) or pharmaceutically acceptable salts thereof are prepd. Thus, 1-(3'-deoxy-3'-fluoro-.beta.-D-

arabinofuranosyl)thymine (prepn. given) was benzoylated by benzoyl chloride in pyridine and alkylated by monomethoxytrityl chloride in pyridine to give 1-(5'-O-monomethoxytrityl-3'-deoxy-3'-fluoro-.beta.-D-arabinofuranosyl)-3-benzoylthymine, which was methylated by MeI in the presence of silver oxide in acetone and treated with satd. NH3 in MeOH and then 80% aq. AcOH to give 1-(3'-fluoro-2'-methoxy-2',3'-dideoxy-.beta.-D-arabinofuranosyl)thymine (II). II at 10 .mu.g/mL and 5-chloro-1-(3'-fluoro-2',3'-dideoxy-.beta.-D-ribofuranosyl)uracil at 0.04 .mu.g/mL inhibited 85 and 50%, resp., HIV multiplication in H9 cell culture.


IT **178374-46-4P 178374-47-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of (fluorodideoxy-.beta.-D-ribofuranosyl)pyrimidine nucleosides as **antiviral** agents against HIV)

RN 178374-46-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-2-O-methyl-.beta.-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178374-47-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-2-O-methyl-.beta.-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **99614-77-4P 124493-83-0P 178374-50-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of (fluorodideoxy-.beta.-D-ribofuranosyl)pyrimidine nucleosides as **antiviral** agents against HIV)

RN 99614-77-4 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 124493-83-0 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178374-50-0 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 3-benzoyl-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L6 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1992:15354 CAPLUS  
 DOCUMENT NUMBER: 116:15354  
 TITLE: 3'-Substituted thymine .alpha.-L-nucleoside derivatives as potential **antiviral** agents: synthesis and biological evaluation  
 AUTHOR(S): Genu-Dellac, C.; Gosselin, G.; Aubertin, A. M.; Obert, G.; Kirn, A.; Imbach, J. L.  
 CORPORATE SOURCE: Univ. Montpellier II, Montpellier, 34095, Fr.  
 SOURCE: Antiviral Chemistry & Chemotherapy (1991), 2(2), 83-92  
 CODEN: ACCHEH; ISSN: 0956-3202  
 DOCUMENT TYPE: Journal

LANGUAGE:  
GI

English



AB Hitherto unknown 1-(3-deoxy-3-substituted-.alpha.-L-lyxofuranosyl)thymines and their 2'-deoxy derivs. related to 3'-azidothymidine (AZT) and its congeners were synthesized and their **antiviral** properties examd. They were prepd. by nucleophilic substitution with inversion of configuration from 3'-O-trifluoromethanesulfonate .alpha.-L-arabinofuranonucleosides and their 2'-deoxy derivs. All the compds. (e.g., I) were tested for their activity against a variety of RNA and DNA viruses, but they did not show significant **antiviral** activity.


IT 137608-98-1P 137609-00-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and **antiviral** activity of, structure in relation to)

RN 137608-98-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-.alpha.-L-lyxofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 137609-00-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.alpha.-L-lyxofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L6 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1991:492834 CAPLUS  
 DOCUMENT NUMBER: 115:92834  
 TITLE: Preparation of deoxyfluoro nucleosides for treatment  
 of AIDS and pharmaceutical compositions containing  
 them  
 INVENTOR(S): Matthes, Eckart; Lehmann, Christine; Scholz, Dieter;  
 Von Janta-Lipinski, Martin; Gaertner, Klaus; Langen,  
 Peter; Rosenthal, Hans Alfred  
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.  
 SOURCE: U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 65,952,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4963662	A	19901016	US 1988-223677	19880715
DD 279407	A1	19900606	DD 1986-292826	19860724
DD 281346	A5	19900808	DD 1987-303489	19870603
AU 8812592	A1	19881110	AU 1988-12592	19880303
AU 615431	B2	19911003		
CA 1333390	A1	19941206	CA 1988-571404	19880707
US 5153180	A	19921006	US 1990-566486	19900813
CA 1336820	A1	19950829	CA 1994-616868	19940531
PRIORITY APPLN. INFO.:			DD 1986-292826	19860724
			DD 1987-302573	19870508
			DD 1987-303489	19870603
			US 1987-65952	19870624
			CA 1988-571404	19880707
			US 1988-223677	19880715

OTHER SOURCE(S): MARPAT 115:92834  
 GI



I

AB The title compds. [I; R1 = (substituted) adenine, cytosine, guanine,  
 thymine, or uracil residue; R2 = H, OH; R3 = OH, acyloxy, (HO)2P(O)O] were  
 prepd. Palmitoyl chloride was added to a soln. of 3'-deoxy-3'-

fluorothymidine in pyridine at 0.degree. and the resulting soln. warmed slowly to room temp. When the reaction was complete (by thin layer chromatog.), the mixt. was poured into ice water to give I [R1 = thymine residue, R2 = H, R3 = plamitoyloxy). 2',3'-Dideoxy-3'-fluorothymidine (II) (prepn. not given) had an ED50 of 0.003 .mu.M against HIV replication in MT-4 cells in vitro. Because of the ability of I to be phosphorylated in the infected cells I were more effective in inhibiting both HIV-1 and HIV-2 than other 3'-modified deoxy nucleosides. Uncoated and coated tablets as well as an injection soln. contg. II were formulated.


IT 56287-14-0P 124493-83-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, for treatment of AIDS)

RN 56287-14-0 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 124493-83-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:450176 CAPLUS

DOCUMENT NUMBER: 115:50176

TITLE: Synthesis and **antiviral** and cytostatic  
properties of 3'-deoxy-3'-fluoro- and  
2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of  
natural heterocyclic bases

AUTHOR(S): Mikhailopulo, I. A.; Poopeiko, N. E.; Prikota, T. I.;  
Sivets, G. G.; Kvasyuk, E. I.; Balzarini, J.; De  
Clercq, Erik

CORPORATE SOURCE: Inst. Bioorg. Chem., Minsk, 220600, USSR


SOURCE: Journal of Medicinal Chemistry (1991), 34(7), 2195-202  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S):  
GI


CASREACT 115:50176



AB A series of 3'-deoxy-3'-fluoro- and 2'-azido-2',3'-dideoxy-3'-fluoro-D-ribofuranosides of natural heterocyclic bases were synthesized with the use of universal carbohydrate precursors, viz., 1-O-acetyl-2,5-di-O-benzoyl-3-deoxy-3-fluoro-D-ribofuranose and Me 2-azido-5-O-benzoyl-2,3-dideoxy-3-fluoro-.beta.-D-ribofuranoside, resp. The cytostatic and **antiviral** activities of the compds. were evaluated against a variety of tumor cell lines and DNA/RNA viruses, resp. As the most active compd., from both a cytostatic and **antiviral** activity viewpoint, emerged 3'-deoxy-3'-fluoroadenosine (I). It inhibited the proliferation of some tumor cell lines (i.e. murine leukemia L1210 and human T-lymphocyte MT-4) at a concn. of 0.2-2 .mu.g/mL, and proved inhibitory to the replication of pos.-stranded RNA viruses (i.e. polio, Cocksackie, Sindbis, Semliki forest), double-stranded RNA viruses (i.e. reo), and some DNA viruses (i.e. vaccinia) at a concn. of 1-4 .mu.g/mL, which is well below the cytotoxicity threshold (40 .mu.g/mL).


IT **57944-13-5P 123402-20-0P 133776-17-7P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and **antiviral** or cytostatic activity of)  
RN 57944-13-5 CAPLUS  
CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-20-0 CAPLUS  
CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 133776-17-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3-(3-deoxy-3-fluoro-.beta.-D-ribofuranosyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:69447 CAPLUS

DOCUMENT NUMBER: 112:69447

TITLE: Synthesis and **antiviral** activity evaluation  
of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum  
**antiviral** activity of 3'-fluoro-3'-  
deoxyadenosine

AUTHOR(S): Van Aerschot, A.; Herdewijn, P.; Janssen, G.; Cools,  
M.; De Clercq, E.

CORPORATE SOURCE: Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain,  
B-3000, Belg.


SOURCE: Antiviral Research (1989), 12(3), 133-50

CODEN: ARSRDR; ISSN: 0166-3542

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Five 3-fluorinated ribonucleosides (I, B = uridine, cytidine, thymine, adenine and inosine) were prepd. and evaluated for their inhibitory properties against different viruses. The compds. were prepd. by treatment of 2',5'-di-O-tritylated nucleoside and analogs possessing a xylo-configuration with diethylaminosulfur trifluoride, followed by deprotection. 3'-Fluoro-3'-deoxyadenosine (I, B = adenine) (II) was active against a broad range of viruses, encompassing both DNA viruses



[pox (vaccinia)], single-stranded (+) RNA viruses [picorna (polio, Coxsackie B), toga (sindbis; Semliki Forest)] and double-stranded RNA viruses (reo). In its **antiviral** activity spectrum, II clearly differed from those adenosine analogs that are known as inhibitors of S-adenosylhomocysteine hydrolase. II also was effective in vivo, in inhibiting tail lesion formation in mice inoculated i.v. with vaccinia virus.


IT 57944-13-5P 123402-20-0P 125217-37-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and virucidal activity of)

RN 57944-13-5 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-20-0 CAPLUS

CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 CAPLUS

CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1987:400316 CAPLUS  
 DOCUMENT NUMBER: 107:316  
 TITLE: A proposed mechanism for the selective inhibition of human cytomegalovirus replication by 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-fluorouracil  
 AUTHOR(S): Suzuki, Satoru; Misra, Hemant K.; Wiebe, Leonard I.; Knaus, Edward E.; Lorne, D.; Tyrrell, J.  
 CORPORATE SOURCE: Fac. Pharm., Univ. Alberta, Edmonton, AB, T6G 2H7, Can.  
 SOURCE: Molecular Pharmacology (1987), 31(3), 301-6  
 CODEN: MOPMA3; ISSN: 0026-895X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The biol. activities of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-fluorouracil (2'-F-ara-FU), and 1-(3'-deoxy-3'-fluoro-.beta.-D-arabinofuranosyl)-5-fluorouracil (3'-F-ara-FU) were compared in human cytomegalovirus (HCMV)-infected and noninfected human fibroblasts. 2'-F-ara-FU inhibited HCMV plaque formation at lower concns. than 3'-F-ara-FU. These nucleoside analogs are expected to be phosphorylated to their 5'-phosphate forms by cellular thymidine kinase in HCMV-infected cells. Cellular thymidine kinase was increased in the virus-infected cells and showed better phosphorylation of 2'-F-ara-FU of did 3'-F-ara-FU. HCMV DNA polymerase was purified by affinity column chromatog., and the inhibitory effect of the 5'-triphosphate derivs. of 2'-F-ara-FU (2'-F-ara-FUTP) and 3'-F-ara-FU (3'-F-ara-FUTP) against viral and host DNA polymerase .alpha. was examd. No significant difference in the effectiveness of inhibition was obsd. between viral DNA polymerase and host polymerase .alpha.. However, viral polymerase incorporated 2'-F-ara-FUTP into newly synthesized DNA, whereas polymerase .alpha. did not utilize 2'-F-ara-FUTP as a substrate. Thus, viral polymerase differs from host polymerase .alpha. in its recognition and utilization of 2'-F-ara-FUTP. This difference may be important to the design of selective **antiviral** agents for HCMV.


IT 19325-94-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (fluorination of)

RN 19325-94-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 108572-20-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and human cytomegalovirus replication inhibition by)

RN 108572-20-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
 5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 108572-21-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and viral and .alpha. DNA polymerases inhibition by)

RN 108572-21-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-  
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-D-  
arabinofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 19 MEDLINE

ACCESSION NUMBER: 88013803 MEDLINE

DOCUMENT NUMBER: 88013803 PubMed ID: 2821379

TITLE: [The effect of 3'-azido-2',3'-dideoxythymidine on  
experimental viral infections].

Deistvie 3'-azido-2',3'-didezoksitimidina na  
eksperimental'nye virusnye infektsii.

AUTHOR: Shneider M A; Rudenko N K; Kavsan V M; Bibilashvili R Sh;  
Kraevskii A A

SOURCE: MOLEKULIARNAIA BIOLOGIIA, (1987 May-Jun) 21 (3) 837-46.  
Journal code: 0105454. ISSN: 0026-8984.

PUB. COUNTRY: USSR

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Russian

FILE SEGMENT: Priority Journals; AIDS

ENTRY MONTH: 198710

ENTRY DATE: Entered STN: 19900305

Last Updated on STN: 19970203

Entered Medline: 19871026

AB 3'-Azido-2',3'-dideoxythymidine (az-T) inhibited effectively the  
reproduction of some retroviruses; among these viruses were the four  
serological subgroups of sarcoma Raus virus in chicken embryo, avian  
myeloblastosis virus and erythroblastosis virus in chicken. This  
inhibition was specific towards retroviruses and practically was not  
observed in the case of infections DNA- and RNA-genome model viruses of  
vaccinia and influenza, at whose reproduction reverse transcriptase is not  
involved. Three other 3'-modified nucleosides did not block the

above-listed retroviruses. For chickens, az-T showed low toxicity. The molecular mechanisms of the action of az-T are discussed.

L6 ANSWER 15 OF 19 USPATFULL

ACCESSION NUMBER: 2003:11137 USPATFULL

TITLE: Anti-HCV nucleoside derivatives

INVENTOR(S): Devos, Rene, Welwyn Garden City, UNITED KINGDOM  
Dymock, Brian William, St. Albans, UNITED KINGDOM  
Hobbs, Christopher John, Hertford, UNITED KINGDOM  
Jiang, Wen-Rong, Welwyn Garden City, UNITED KINGDOM  
Martin, Joseph Armstrong, Harpenden, UNITED KINGDOM  
Merrett, John Herbert, Baldock, UNITED KINGDOM  
Najera, Isabel, St. Albans, UNITED KINGDOM  
Shimma, Nobuo, Chigasaki-shi, JAPAN  
Tsukuda, Takuo, Odawara-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008841	A1	20030109
APPLICATION INFO.:	US 2001-923620	A1	20010807 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-21285	20000830
	GB 2000-26611	20001031

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340  
KINGSLAND STREET, NUTLEY, NJ, 07110  
NUMBER OF CLAIMS: 49  
EXEMPLARY CLAIM: 1  
LINE COUNT: 4872  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 26563-01-9P 125217-37-0P 129885-95-6P  
(prepn. of antiviral nucleoside derivs. as inhibitors of subgenomic hepatitis C virus RNA replication).

RN 26563-01-9 USPATFULL

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125217-37-0 USPATFULL


CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 USPATFULL  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 19 USPATFULL  
 ACCESSION NUMBER: 2002:32541 USPATFULL  
 TITLE: Method for the treatment or prevention of flavivirus  
 infections using nucleoside analogues  
 INVENTOR(S): Ismaili, Hicham Moulay Alaoui, Montreal, CANADA  
 Cheng, Yun-Xing, Dollard-des-Ormeaux, CANADA  
 Lavallee, Jean-Francois, Bellefeuille, CANADA  
 Siddiqui, Arshad, Dollard-des-Ormeaux, CANADA  
 Storer, Richard, Baie d'Urfe, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019363	A1	20020214
APPLICATION INFO.:	US 2001-785235	A1	20010220 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183349P	20000218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, PC, 2200 CLARENDON BLVD, SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1165	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 70580-87-9 85708-20-9 123402-20-0


123402-25-5

(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 USPATFULL

CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 85708-20-9 USPATFULL

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-20-0 USPATFULL

CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123402-25-5 USPATFULL

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 17 OF 19 USPATFULL

ACCESSION NUMBER: 96:29544 USPATFULL

TITLE: 1-(3'-fluoro-2',3'-dideoxy-.beta.-D-ribofuranosyl)-5-substituted pyrimidine nucleosides

INVENTOR(S): Johansson, Karl N. G., Enhorna, Sweden  
Lindborg, BjoG., Avsjo, Sweden  
Norinder, Ulf, Sodertalje all of, Sweden  
Stening, Goran B., Sodertalje all of, Sweden

PATENT ASSIGNEE(S): Medivir AB, Huddinge, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5506215		19960409
APPLICATION INFO.:	US 1994-354769		19941212 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-802706, filed on 6 Dec 1991, now abandoned which is a continuation of Ser. No. US 1990-518495, filed on 3 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-266402, filed on 2 Nov 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1987-4298	19871103
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kunz, Gary L.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1253	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A 2',3'-deoxy-3'-fluoro-pyrimidine nucleoside having the formula:  
##STR1## wherein R<sup>sup.1</sup> is OH or NH<sub>sub.2</sub> ;

R<sup>sup.2</sup> is CF<sub>sub.3</sub>, CH<sub>sub.2</sub> CH<sub>sub.2</sub> CH<sub>sub.3</sub>, ##STR2## CH<sub>sub.2</sub> OCH<sub>sub.3</sub>, CH<sub>sub.2</sub> SCH<sub>sub.3</sub>, CH<sub>dbd</sub>.CH<sub>sub.2</sub> CH<sub>dbd</sub>.CH--CH<sub>sub.3</sub>, C.tbd.CH, C.tbd.C--CH<sub>sub.3</sub> or CH<sub>sub.2</sub> --C.tbd.CH;

or a pharmaceutically acceptable salt thereof.

These nucleoside analogs exhibit **antiviral** activity against HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 178374-46-4P 178374-47-5P

(prepn. of (fluorodideoxy-.beta.-D-ribofuranosyl)pyrimidine nucleosides as antiviral agents against HIV)

RN 178374-46-4 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-2-O-methyl-.beta.-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178374-47-5 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-2-O-methyl-.beta.-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 99614-77-4P 124493-83-0P 178374-50-0P

(prepn. of (fluorodideoxy-.beta.-D-ribofuranosyl)pyrimidine nucleosides as antiviral agents against HIV)

RN 99614-77-4 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 124493-83-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 178374-50-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 3-benzoyl-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 18 OF 19 USPATFULL

ACCESSION NUMBER: 92:82761 USPATFULL

TITLE: Fluorinated nucleosides and process for treating retrovirus infections therewith

INVENTOR(S): Matthes, Eckart, Karower Chaussee 129, 1115 Berlin, Germany, Federal Republic of  
 Lehmann, Christine, Walter-Friedrich Str. 5, 1055 Berlin, Germany, Federal Republic of  
 Scholz, Dieter, Heinrich-Roller Str. 16, 1055 Berlin, Germany, Federal Republic of  
 von Janta-Lipinski, Martin, Pradelstr. 6, 1100 Berlin, Germany, Federal Republic of  
 Gaertner, Klaus, Karower Chaussee 157, 1115 Berlin, Germany, Federal Republic of  
 Langen, Peter, Karower Chaussee 219, 1115 Berlin, Germany, Federal Republic of  
 Rosenthal, Hans-Alfred, Markisches Ufer 14, 1020 Berlin, Germany, Federal Republic of

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5153180		19921006
APPLICATION INFO.:	US 1990-566486		19900813 (7)
DISCLAIMER DATE:	20071016		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-223677, filed on 15 Jul 1988, now patented, Pat. No. US 4963662 which is a continuation of Ser. No. US 1987-65952, filed on 24 Jun 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		

LEGAL REPRESENTATIVE: Schweitzer Cornman & Gross  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
LINE COUNT: 805  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for treating AIDS, which comprises administering to a patient in need therefor a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula ##STR1## wherein: R.sub.1 is an adenine, cytosine, guanine, thymidine, uracil, 5-substituted uracil, 5-substituted cytosine derivative, 2-fluoroadenine, 2,6-diaminopurine, 2-aminopurine, 6-thioguanine, or 7-deazaadenine group;

R.sub.2 is H, or a OH group;

R.sub.3 is a OH, O-acyl, O-palmitoyl group or phosphates (as free acid, or its alkali, ammonium or alkyl ammonium salts), or any other precursor group for the hydroxyl group;

or a physiologically acceptable salt thereof. Furthermore, the present invention comprises the new compounds:

2',3'-dideoxy-3'-fluoro-2-fluoroadenosine,

2',3'-dideoxy-3'-fluoro-6-thioguanosine,

2',3'-dideoxy-3'-fluoro-2,6-diaminopurineriboside,

2',3'-dideoxy-3'-fluoro-2-aminopurineriboside,

2',3'-dideoxy-3'-fluoro-5-aminomethyluridine,

2',3'-dideoxy-3'-fluoro-5-azidomethyluridine, and

2',3'-dideoxy-3'-fluoro-5-hydroxymethyluridine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 56287-14-0P

(prepn. of, for treatment of AIDS)

RN 56287-14-0 USPATFULL

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 19325-94-1

(reaction of, in prepn. of drug for treatment of AIDS)

RN 19325-94-1 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 56287-14-0

(use of, for treatment of AIDS)

RN 56287-14-0 USPATFULL

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 19 OF 19 USPATFULL

ACCESSION NUMBER: 90:79990 USPATFULL

TITLE: Fluorinated nucleosides and method for treating retrovirus infections therewith

INVENTOR(S): Matthes, Eckart, Berlin, German Democratic Republic  
Lehmann, Christine, Berlin, German Democratic Republic  
Scholz, Dieter, Berlin, German Democratic Republic  
von Janta-Lipinski, Martin, Berlin, German Democratic Republic  
Gaertner, Klaus, Berlin, German Democratic Republic  
Langen, Peter, Berlin, German Democratic Republic  
Rosenthal, Hans-Alfred, Berlin, German Democratic Republic

PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Berlin, German Democratic Republic (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4963662		19901016
APPLICATION INFO.:	US 1988-223677		19880715 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-65952, filed on 24 Jun 1987, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DD 1986-2928263	19860724
	DD 1987-3025732	19870508
	DD 1987-3034896	19870603

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Rollins, John W.  
LEGAL REPRESENTATIVE: Schweitzer Cornman & Gross  
NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1  
LINE COUNT: 810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating AIDS, which comprises administering to a patient in need therefor a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula ##STR1## wherein R.sub.1 is an adenine, cytosine, guanine, thymidine, uracil, 5-substituted uracil, 5-substituted cytosine derivative, 2-fluoroadenine, 2,6-diaminopurine, 2-aminopurine, 6-thioguanine, or 7-deazaadenine group;

R.sub.2 is H, or a OH group;

R.sub.3 is a OH, O-acyl, O-palmitoyl group, or phosphates (as free acid, or its alkali, ammonium or alkyl ammonium salts), or any other precursor group for the hydroxyl group;

or a physiologically acceptable salt thereof. Furthermore, the present invention comprises the new compounds:

2',3'-dideoxy-3'-fluoro-2-fluoroadenosine,

2',3'-dideoxy-3'-fluoro-6-thioguanosine,

2',3'-dideoxy-3'-fluoro-2,6-diaminopurineriboside,

2',3'-dideoxy-3'-fluoro-2-aminopurineriboside,

2',3'-dideoxy-3'-fluoro-5-aminomethyluridine,

2',3'-dideoxy-3'-fluoro-5-azidomethyluridine, and

2',3'-dideoxy-3'-fluoro-5-hydroxymethyluridine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 56287-14-0P 124493-83-0P

(prepn. of, for treatment of AIDS)

RN 56287-14-0 USPATFULL

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 124493-83-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-  
5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>